Aligos Therapeutics (NASDAQ:ALGS) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research report released on Thursday morning, MarketBeat.com reports. The firm issued a buy rating and a $48.00 target price on the stock.

Several other research firms have also commented on ALGS. UBS Group started coverage on Aligos Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $20.00 target price on the stock. Wall Street Zen downgraded Aligos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $39.33.

Aligos Therapeutics Price Performance

NASDAQ ALGS opened at $6.81 on Thursday. Aligos Therapeutics has a 1 year low of $3.76 and a 1 year high of $13.69. The company has a market capitalization of $42.15 million, a PE ratio of -0.79 and a beta of 2.67. The company has a fifty day moving average of $7.48 and a 200 day moving average of $8.85.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share for the quarter, topping the consensus estimate of ($2.09) by $0.18. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.27 million. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%. Research analysts expect that Aligos Therapeutics will post -10.36 earnings per share for the current year.

Institutional Trading of Aligos Therapeutics

Several institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. raised its stake in shares of Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after buying an additional 9,000 shares during the period. NorthCrest Asset Manangement LLC acquired a new stake in Aligos Therapeutics in the 3rd quarter valued at $98,000. Susquehanna International Group LLP purchased a new stake in Aligos Therapeutics in the 3rd quarter worth $99,000. XTX Topco Ltd purchased a new stake in Aligos Therapeutics in the 2nd quarter worth $100,000. Finally, HRT Financial LP acquired a new position in Aligos Therapeutics during the fourth quarter worth $106,000. 60.43% of the stock is owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.